{
  "docId": "019de076-f978-76c3-9c95-6b6ce7102162",
  "docSlug": "c02a1d1cb7557bc430cc8dc61cd27097",
  "documentTitle": "CG Oncology | IPO Presentation Deck | 45 slides",
  "authorId": "cg-oncology",
  "authorName": "CG Oncology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 14,
  "pageCount": 45,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "why_now",
  "function": "argue_timing",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide highlights the regulatory environment as a key driver for development, citing specific FDA definitions and successful approvals.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/14",
  "deckHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162",
  "deckJsonHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json",
  "deckAnchorHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.75,
        "y": 0.25
      },
      "kind": "callout",
      "text": "Two Therapeutic Agents Approved for Full Approval Following Issuance of FDA Guidance*",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ab9fd8a-59f9-4585-8d9f-8e7009ab6238",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.78,
        "y": 0.45
      },
      "kind": "image",
      "text": "MERCK",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "855455d2-a8a4-44cc-a776-c2164826f274",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.78,
        "y": 0.58
      },
      "kind": "image",
      "text": "FERRING PHARMACEUTICALS",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "affc7eec-5695-4fb7-b1d2-61c3c09efa49",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.65,
        "x": 0.03,
        "y": 0.3
      },
      "kind": "list",
      "text": "BCG-unresponsive disease defined as either: Persistent or recurrent CIS alone or with recurrent Ta/T1 disease within 12 months of adequate BCG therapy; Recurrent high-grade Ta/T1 disease within 6 months of completion of adequate BCG therapy, or; T1 high-grade disease following a BCG induction course.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e0e2fd3-bcfe-4043-917c-1c239c9c89ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.85
      },
      "kind": "paragraph",
      "text": "Patient aversion to radical cystectomy associated with significant change in daily routine, surgery-related complications, and mortality rate drives regulatory and sponsor development.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0394054a-1c03-4e56-b20c-6dc7a1f5a280",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.65,
        "x": 0.03,
        "y": 0.6
      },
      "kind": "paragraph",
      "text": "Adequate BCG therapy is defined as at least 5 doses of induction course plus at least 2 doses of maintenance therapy, or at least 5 doses of induction plus at least 2 doses of second induction.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b22cf24-eec1-4f26-b644-bab881863245",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.65,
        "x": 0.03,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Single-arm trials with complete response rate as primary endpoint in the context of duration of response may be appropriate for a full approval.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50ed021b-949b-4c18-b367-2599fd3a4f45",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "FDA Guidance on BCG-Unresponsive NMIBC De-Risks Development & Regulatory Pathway to BLA Approval",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f858841-8524-4529-bd68-7f690d955ec3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem-Agitate-Solve (PAS)",
      "slug": "problem-agitate-solve-pas",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "5a38801c-9906-4a5a-ad99-fbd4e5abc5bd",
      "evidence": "Patient aversion to radical cystectomy associated with significant change in daily routine, surgery-related complications, and mortality rate drives regulatory and sponsor development.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 40,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed",
      "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').",
      "position": 0,
      "objective": "What are the consequences of not adopting Cretostimogene?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 15,
      "from": 13,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "6f9edf1b-df40-4ee7-a622-285d4d2d2fff",
      "evidence": "The loop is opened on slide 13 ('The Patient Journey') and closed on slide 15 ('Focused Execution Towards Becoming the Leader in High-Risk and Intermediate-Risk Markets').",
      "position": 1,
      "objective": "What are the needs of patients with bladder cancer?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}